Figure 2
Effects of central administration of recombinant mouse interleukin-1β (IL-1β) to Swiss Webster mice. (a) IL-1β produced dose-dependent increases in immobility time in the tail suspension and (b) forced swim test indicative of a depressive-like effect (*P<0.05 vs vehicle-treated control; n=). (c) IL-1β produced significant increases in sickness behavioral score at the same doses that produce depressive-like behaviors (*P<0.05 vs vehicle-treated control; n=15–26 per treatment group). (d) Central administration of recombinant mouse IL-1β produced significant increases in IL-1β protein levels in the cortex of mice as measured via multiplex enzyme-linked immunosorbent assay (ELISA) (*P<0.05; n=4–6 per treatment group). (e) Central administration of recombinant mouse IL-1β produced significant increases in IL-6 protein levels in the cortex of mice as measured via multiplex ELISA (*P<0.05; n=4–6 per treatment group). I.c.v., intracerebroventricularly; veh, vehicle.
